Travere Therapeutics (TVTX) Tax Provisions (2014 - 2026)
Travere Therapeutics (TVTX) reported Tax Provisions of -$120000.0 for Q1 2026, down 407.69% on a YoY basis from $39000.0 in Q1 2025, and down 113.03% quarter-over-quarter from $921000.0 in Q4 2025.
Travere Therapeutics (TVTX) Tax Provisions (2014 - 2026) Analysis & Trends
Travere Therapeutics has reported Tax Provisions for 13 years, with the latest figure at -$120000.0 in Q1 2026.
- For the quarter ending Q1 2026, Tax Provisions fell 407.69% year-over-year to -$120000.0; the trailing twelve-month figure through Mar 2026 stood at $829000.0 (up 2690.62% YoY), and the FY2025 full-year result was $988000.0, up 723.33% from the prior year.
- Tax Provisions for Q1 2026 stood at -$120000.0, down from $921000.0 in the prior quarter.
- The five-year high for Tax Provisions was $921000.0 in Q4 2025, with the low at -$120000.0 in Q1 2026.
- Historically, Tax Provisions has averaged $89647.1 across 5 years, with a median of $53000.0 in 2022.
- Annual changes were most pronounced in 2022 — Tax Provisions jumped 1475.0% — and 2024, when it plunged 800.0%.
- Travere Therapeutics' Tax Provisions stood at $63000.0 in 2022, then rose by 7.94% to $68000.0 in 2023, then sank by 205.88% to -$72000.0 in 2024, then soared by 1379.17% to $921000.0 in 2025, then slumped by 113.03% to -$120000.0 in 2026.
- The last three Tax Provisions figures came in at -$120000.0 (Q1 2026), $921000.0 (Q4 2025), and $8000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -11.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 216,000.00 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -859,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 221.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Travere Therapeutics | 5.07 Bn | 4.99 Bn | 102.38 Mn | -120,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -120,000.00 |
| Dec 31, 2025 | 921,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 20,000.00 |
| Mar 31, 2025 | 39,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | -84,000.00 |
| Jun 30, 2024 | 85,000.00 |
| Mar 31, 2024 | 191,000.00 |
| Dec 31, 2023 | 68,000.00 |
| Sep 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 65,000.00 |
| Mar 31, 2023 | 78,000.00 |
| Dec 31, 2022 | 63,000.00 |
| Sep 30, 2022 | 145,000.00 |
| Jun 30, 2022 | 53,000.00 |
| Mar 31, 2022 | 52,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 43,000.00 |
| Jun 30, 2021 | 49,000.00 |